Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Lynch on Expanding Molecular Subsets in NSCLC

March 25th 2015

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses expanding the number of molecular subsets in non-small cell lung cancer (NSCLC).

Hollings Cancer Center Interim Director Anthony J. Alberg, Ph.D., Part of Institute of Medicine Committee Convened to Study Minimum Age for Tobacco Purchases

March 21st 2015

Increasing the minimum age of legal access (MLA) to tobacco products will prevent or delay initiation of tobacco use by adolescents and young adults, particularly those ages 15 to 17, and improve the health of Americans across the lifespan.

Three FDA Approvals, NCI Director Resigns, and More

March 12th 2015

Lung Cancer Clinical Trials Could See Boost in Enrollment

March 9th 2015

Prior cancer history should not exclude patients with advanced lung cancer from participating in clinical trials because it does not impact clinical outcomes.

New Targeted Therapy Strategies on Horizon in NSCLC

March 9th 2015

OncLive sat down with Edward Kim, MD, to learn more about the impact of recent advances in NSCLC and what the future treatment paradigm might look like.

FDA Approves Nivolumab for Lung Cancer

March 4th 2015

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

Nivolumab Receives Priority Review for NSCLC

February 27th 2015

The FDA has granted a priority review to nivolumab for use in patients with previously treated, advanced, squamous non–small cell lung cancer.

Future Treatment Strategies for NSCLC

February 27th 2015

Development of Rociletinib and AZD9291 in NSCLC

February 27th 2015

Third-Generation EGFR Inhibitors in NSCLC

February 27th 2015

Personalized Medicine in NSCLC

February 27th 2015

Clinical Utility of PD-L1 as a Biomarker in Lung Cancer

February 27th 2015

Immunotherapy in Non-Small Cell Lung Cancer

February 27th 2015

Intricacies of Checkpoint Inhibition in NSCLC

February 27th 2015

Promise of Immunotherapy in Lung Cancer

February 27th 2015

Checkpoint Inhibition for Mesothelioma, Thymic Malignancies

February 27th 2015

Necitumumab in Squamous NSCLC

February 27th 2015

Ramucirumab in Metastatic NSCLC

February 27th 2015

Maintenance Combination Therapy in NSCLC

February 27th 2015

Chemotherapy Regimens in Metastatic NSCLC

February 27th 2015

NEXT PAGE
PREVIOUS PAGE